# PIVOT-09 (NCT03729245)

> A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03729245
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Nektar Therapeutics
- Conditions: Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
- Interventions: bempegaldesleukin; sunitinib; nivolumab; cabozantinib
- Enrollment: 623
- Primary outcome: Objective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC
- Primary outcome: Overall Survival (OS) in IMDC All-Risk and Intermediate- or Poor-risk Patients With Previously Untreated Advanced RCC

## Indexed commentary on PIVOT-09 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=pivot-09-nct03729245

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03729245", "email": "<work email>"}; the inbox owner confirms by the emailed link.